Truist lowered the firm’s price target on Arcus Biosciences (RCUS) to $30 from $39 and keeps a Buy rating on the shares. Arcus ended the Phase 3 STAR-221 trial after a futile analysis, eliminating domvanalimab+zmberelimab as a near-term catalyst and heightening pessimism around the broader TIGIT program, including Dom in non-small cell lung cancer, the analyst tells investors in a research note. Large R&D cuts are expected as the company pivots toward casdatifan, which remains a potential multi-billion-dollar opportunity backed by about $1B in cash and multiple 2026 catalysts.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences: Strategic Focus and Financial Positioning Drive Buy Rating
- Arcus Biosciences price target raised to $32 from $28 at H.C. Wainwright
- Arcus Biosciences falls -11.2%
- Arcus Biosciences Stock (RCUS) Collapses 17% after Failed Stomach Cancer Study
- Arcus Biosciences Ends Phase 3 STAR-221 Study